- Home
- TARA vs ATOS Comparison
TARA vs ATOS Comparison
Compare TARA & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- ATOS
- Stock Information
- Founded
- TARA N/A
- ATOS 2009
- Country
- TARA United States
- ATOS United States
- Employees
- TARA N/A
- ATOS N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- TARA Health Care
- ATOS Health Care
- Exchange
- TARA Nasdaq
- ATOS Nasdaq
- Market Cap
- TARA 118.1M
- ATOS 107.2M
- IPO Year
- TARA N/A
- ATOS 2012
- Fundamental
- Price
- TARA $3.03
- ATOS $0.78
- Analyst Decision
- TARA Strong Buy
- ATOS Strong Buy
- Analyst Count
- TARA 7
- ATOS 3
- Target Price
- TARA $20.67
- ATOS $6.17
- AVG Volume (30 Days)
- TARA 214.2K
- ATOS 1.3M
- Earning Date
- TARA 08-11-2025
- ATOS 08-12-2025
- Dividend Yield
- TARA N/A
- ATOS N/A
- EPS Growth
- TARA N/A
- ATOS N/A
- EPS
- TARA N/A
- ATOS N/A
- Revenue
- TARA N/A
- ATOS N/A
- Revenue This Year
- TARA N/A
- ATOS N/A
- Revenue Next Year
- TARA N/A
- ATOS N/A
- P/E Ratio
- TARA N/A
- ATOS N/A
- Revenue Growth
- TARA N/A
- ATOS N/A
- 52 Week Low
- TARA $1.60
- ATOS $0.55
- 52 Week High
- TARA $10.48
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- TARA 44.29
- ATOS 42.24
- Support Level
- TARA $3.06
- ATOS $0.81
- Resistance Level
- TARA $3.33
- ATOS $0.80
- Average True Range (ATR)
- TARA 0.17
- ATOS 0.04
- MACD
- TARA -0.01
- ATOS -0.01
- Stochastic Oscillator
- TARA 4.65
- ATOS 7.50
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.